

Ninth International Congress on the Future of Breast Cancer

Estancia La Jolla Hotel
La Jolla, CA
July 22-25, 2010

Agenda Last Updated: September 9, 2010 (be sure to check that this agenda is the latest version)

Thursday, Jul 22, 2010

12:00 pm	Registration	
12:30 pm	Welcome and Introductions	
12:40 pm	Keynote: Breast Cancer Steroid Receptor Targets	<i>Ronald M. Evans</i>
1:05 pm	Pre-session Survey	
Best of Breast Cancer Science: Breast Cancer–Initiating Cells		
1:15 pm	Breast Cancer Heterogeneity and Metastases	<i>Joseph R. Nevins</i>
1:40 pm	Tracking and Targeting Breast Cancer–Initiating Cells	<i>Jeffrey M. Rosen</i>
2:05 pm	Best of Breast Cancer Clinical Science: Highlights From 2009	<i>Kathy Albain</i>
2:35 pm	Panel Discussion	
2:55 pm	Break	
Hormone Receptor–Driven Breast Cancer		
3:15 pm	Classification of Hormone Receptor–Positive Breast Cancer	<i>Sunil Badve</i>
3:35 pm	New Insights Into Optimizing Endocrine Therapy: Adjuvant	<i>Stephen E. Jones</i>
3:55 pm	New Insights Into Optimizing Endocrine Therapy: Metastatic	<i>Stefan Glück</i>
4:15 pm	Optimizing Premenopausal Adjuvant Endocrine Therapy: The First 5 Years	<i>Jo Anne Zujewski</i>
4:35 pm	Optimizing Premenopausal Adjuvant Endocrine Therapy: Endocrine Therapy for Life?	<i>Frankie Ann Holmes</i>
4:55 pm	Overcoming Endocrine Therapy Resistance: Views of a Basic Scientist	<i>Suzanne A. W. Fuqua</i>
5:15 pm	Overcoming Endocrine Therapy Resistance: Views of a Clinical Scientist	<i>Douglas Yee</i>
5:35 pm	Post-session Survey	
5:45 pm	Panel Discussion	
6:05 pm	Adjourn	
7:00 pm-9:00 pm	Welcome Reception	

Friday, Jul 23, 2010

6:45 am	Continental Breakfast	
7:15 am	Welcome and Introductions	
7:20 am	Pre-session Survey	
7:25 am	Molecular Determinants of Tumor Invasion and Metastases	<i>Andrea Richardson</i>
HER2-Driven Breast Cancer		
7:50 am	Are There Subtypes of HER2-Positive Breast Cancer?	<i>Debu Tripathy</i>
8:10 am	Is There an Optimal Adjuvant Therapy for HER2-Positive Breast Cancer?	<i>Maureen Trudeau</i>
8:30 am	Overcoming Trastuzumab Resistance: Views From a Basic Scientist	<i>Carlos Arteaga</i>
8:50 am	Overcoming Trastuzumab Resistance: Views From a Clinical Scientist	<i>Edward Romond</i>
9:10 am	Promising New Agents for HER2-Positive Breast Cancer	<i>Joyce O'Shaughnessy</i>
9:30 am	Panel Discussion	
9:50 am	Break	
Antiangiogenic Therapies		
10:10 am	Advancing the Impact of Angiogenesis Inhibitors: Views From a Basic Scientist	<i>Robert Kerbel</i>
10:30 am	Advancing the Impact of Angiogenesis Inhibitors: Views From a Clinical Scientist	<i>Hope S. Rugo</i>
Triple-Negative Breast Cancer		
10:50 am	Classifying Triple-Negative Breast Cancers	<i>Charles Perou</i>
11:10 am	Novel Therapies for Triple-Negative Breast Cancer	<i>Joseph A. Sparano</i>
11:30 am	Treating and Preventing Bone Metastases: Views From a Basic Scientist	<i>Theresa A. Guise</i>
11:50 am	Treating and Preventing Bone Metastases: Views From a Clinical Scientist	<i>Julie R. Gralow</i>
12:10 pm	Novel Cytotoxic Therapies	<i>Hope S. Rugo</i>
12:30 pm	Post-session Survey	
12:40 pm	Panel Discussion	
1:00 pm	Adjourn	
2:30 pm-4:30 pm	Workshop: Novel Therapeutic Agents (Non-CME Activity)	

Saturday, Jul 24, 2010

7:30 am	Continental Breakfast	
8:00 am	Welcome and Introductions	
8:05 am	Obesity and Breast Cancer Outcomes	<i>Rowan Chlebowski</i>
8:25 am	Pre-session Survey	

Locoregional Therapies for Breast Cancer

8:35 am	The Role of Radiation Therapy in DCIS	<i>Beryl McCormick</i>
8:55 am	New Data Affecting Locoregional Management: Sentinel Lymph Node Biopsy and Genomic Profiling	<i>Eleftherios Mamounas</i>
9:15 am	New Insights Into the Prevention and Management of Familial Breast Cancer	<i>David M. Euhus</i>
9:35 am	Hypofractionated Breast Radiation Therapy	<i>Beryl McCormick</i>
9:55 am	Patient Preferences and Decision Analyses in Early Breast Cancer Treatment	<i>Reshma Jagsi</i>
10:15 am	Panel Discussion	
10:35 am	Break	

Clinical Debates

10:55 am	Is Chemotherapy Still Standard for Indolent Hormone Receptor-Positive/Node-Positive Breast Cancer?	
	Green Light	<i>Charles E. Geyer</i>
	Red Light	<i>Kathy Albain</i>
11:25 am	Should Adjuvant Platinum Be Used in High-Risk Triple-Negative Breast Cancer?	
	Green Light	<i>William M. Sikov</i>
	Red Light	<i>Lori J. Goldstein</i>
11:55 am	Post-session Survey	
12:05 pm	Panel Discussion	
12:30 pm	Adjourn	
2:00 pm-4:00 pm	Workshop: Novel Diagnostics (Non-CME Activity)	

Sunday, Jul 25, 2010

7:30 am	Continental Breakfast	
8:00 am	Welcome and Introductions	
8:10 am	Oncology Consultations: Challenging Cases	

Emerging Understanding of Breast Cancer Pathogenesis

9:10 am	Tissue Factor and Breast Cancer	<i>Janusz Rak</i>
---------	----------------------------------------	-------------------

9:30 am	Targets in Circulating Tumor Cells	<i>James M. Reuben</i>
9:50 am	Break	
10:10 am	Pathways Underlying Aggressive Breast Cancers	<i>Philippe Bedard</i>
10:30 am	Genetic Polymorphisms Causing Resistance to Chemotherapy	<i>Christine B. Ambrosone</i>
10:50 am	Novel Combination Therapies With Promise for Metastatic Breast Cancer	<i>Stacy Moulder</i>
11:10 am	Panel Discussion	
11:30 am	Closing Comments	
11:35 am	Adjourn	